Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy Subjects
Completed · Phase 1 · Has a placebo group
Conditions studied: Rheumatoid Arthritis
In brief
AC430 will be administered, orally under fasting conditions (fasting 4 hours before and 2 hours after dosing) with approximately 240 mL of water either once daily or twice daily. It is designed to assess the safety, tolerability, and pharmacokinetics of single and multiple oral doses of AC430.
Key facts
- Study ID
- NCT01287858
- Run by
- Daiichi Sankyo
- People needed
- 88
- Starts
- 2010-11-01
- Expected to finish
- 2011-06-01
- Last updated by the study team
- 2015-11-02
Who can join
Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.
Where it is running
- Covance Clinical Research Unit — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.